WO2023002120A1 - Utilisation du virus torque teno (ttv) en tant que marqueurs pour determiner le risque de complication chez un patient admis au sein d'un etablissement de sante - Google Patents
Utilisation du virus torque teno (ttv) en tant que marqueurs pour determiner le risque de complication chez un patient admis au sein d'un etablissement de sante Download PDFInfo
- Publication number
- WO2023002120A1 WO2023002120A1 PCT/FR2022/051436 FR2022051436W WO2023002120A1 WO 2023002120 A1 WO2023002120 A1 WO 2023002120A1 FR 2022051436 W FR2022051436 W FR 2022051436W WO 2023002120 A1 WO2023002120 A1 WO 2023002120A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ttv
- patient
- viral load
- risk
- biological sample
- Prior art date
Links
- 241000960387 Torque teno virus Species 0.000 title abstract description 278
- 239000003550 marker Substances 0.000 title description 3
- 230000003612 virological effect Effects 0.000 claims abstract description 163
- 238000000034 method Methods 0.000 claims abstract description 121
- 239000012472 biological sample Substances 0.000 claims abstract description 94
- 238000011282 treatment Methods 0.000 claims abstract description 53
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract description 31
- 238000000338 in vitro Methods 0.000 claims abstract description 17
- 241001529453 unidentified herpesvirus Species 0.000 claims description 92
- 239000000523 sample Substances 0.000 claims description 72
- 206010011409 Cross infection Diseases 0.000 claims description 49
- 206010029803 Nosocomial infection Diseases 0.000 claims description 38
- 238000001514 detection method Methods 0.000 claims description 34
- 230000001965 increasing effect Effects 0.000 claims description 28
- 208000014674 injury Diseases 0.000 claims description 27
- 230000008733 trauma Effects 0.000 claims description 23
- 230000036541 health Effects 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 210000002381 plasma Anatomy 0.000 claims description 21
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 16
- 241000701027 Human herpesvirus 6 Species 0.000 claims description 15
- 238000011156 evaluation Methods 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 206010040070 Septic Shock Diseases 0.000 claims description 7
- 230000036303 septic shock Effects 0.000 claims description 7
- 239000013060 biological fluid Substances 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 description 64
- 108020004707 nucleic acids Proteins 0.000 description 60
- 102000039446 nucleic acids Human genes 0.000 description 60
- 108090000623 proteins and genes Proteins 0.000 description 58
- 102000004169 proteins and genes Human genes 0.000 description 58
- 238000012163 sequencing technique Methods 0.000 description 40
- 241000700605 Viruses Species 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 35
- 208000015181 infectious disease Diseases 0.000 description 35
- 238000001356 surgical procedure Methods 0.000 description 29
- 230000003321 amplification Effects 0.000 description 25
- 238000003199 nucleic acid amplification method Methods 0.000 description 25
- 206010040047 Sepsis Diseases 0.000 description 17
- 208000003322 Coinfection Diseases 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 15
- 206010058874 Viraemia Diseases 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000000495 immunoinflammatory effect Effects 0.000 description 11
- 108020005202 Viral DNA Proteins 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 238000003753 real-time PCR Methods 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 230000002596 correlated effect Effects 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000007419 viral reactivation Effects 0.000 description 9
- 208000018811 burn Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 108091023045 Untranslated Region Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 238000007847 digital PCR Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241001339993 Anelloviridae Species 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 238000009007 Diagnostic Kit Methods 0.000 description 5
- 206010062016 Immunosuppression Diseases 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 4
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108020004638 Circular DNA Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241000700586 Herpesviridae Species 0.000 description 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 3
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000012165 high-throughput sequencing Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 2
- 101000588045 Homo sapiens Kunitz-type protease inhibitor 1 Proteins 0.000 description 2
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102100024407 Jouberin Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091092724 Noncoding DNA Proteins 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 2
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 208000007474 aortic aneurysm Diseases 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000011901 isothermal amplification Methods 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 description 1
- 101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 description 1
- 101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 description 1
- 101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 description 1
- 101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 description 1
- 101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 description 1
- 241001339888 Alphatorquevirus Species 0.000 description 1
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 description 1
- 101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 description 1
- 101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 description 1
- 101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 description 1
- 101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 description 1
- 101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 description 1
- 101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 description 1
- 101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 description 1
- 101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001339887 Betatorquevirus Species 0.000 description 1
- 101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241001533399 Circoviridae Species 0.000 description 1
- 101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 102100031725 Cortactin-binding protein 2 Human genes 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010069808 Electrical burn Diseases 0.000 description 1
- 101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 description 1
- 101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 description 1
- 241001339886 Gammatorquevirus Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 description 1
- 101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 description 1
- 101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 description 1
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 description 1
- 241001455657 Human betaherpesvirus 6A Species 0.000 description 1
- 241001455656 Human betaherpesvirus 6B Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 102000000521 Immunophilins Human genes 0.000 description 1
- 108010016648 Immunophilins Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 description 1
- 101150068332 KIT gene Proteins 0.000 description 1
- 101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 description 1
- 101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 description 1
- 101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000023637 Multiple injury Diseases 0.000 description 1
- 101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 101710197985 Probable protein Rev Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 description 1
- 101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 description 1
- 101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 description 1
- 101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 description 1
- 101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 description 1
- 101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 description 1
- 101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 241000332807 TTV-like mini virus Species 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 101150037168 US7 gene Proteins 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 description 1
- 101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 238000004082 amperometric method Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 238000011984 electrochemiluminescence immunoassay Methods 0.000 description 1
- 238000000572 ellipsometry Methods 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007841 sequencing by ligation Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000011410 subtraction method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229960005289 voclosporin Drugs 0.000 description 1
- 108010057559 voclosporin Proteins 0.000 description 1
- BICRTLVBTLFLRD-PTWUADNWSA-N voclosporin Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O BICRTLVBTLFLRD-PTWUADNWSA-N 0.000 description 1
- 238000004832 voltammetry Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
Definitions
- TITLE USE OF THE TORQUE TENO VIRUS (TTV) AS MARKERS TO DETERMINE THE RISK OF COMPLICATION IN A PATIENT ADMITTED TO A HEALTHCARE ESTABLISHMENT
- Hpv herpesvirus
- TTV torque teno virus
- a first object of the present invention relates to a method for in vitro or ex vivo evaluation of the risk of complication in a patient admitted to a healthcare establishment, comprising measuring the viral load of at least one torque teno virus (TTV) in a biological sample from said patient, characterized in that said patient is not under immunosuppressive treatment.
- TTV torque teno virus
- said method is characterized in that the patient is a patient admitted to a hospital, preferably to the emergency department, the resuscitation department, to an intensive care unit or to a ongoing care.
- said method is characterized in that said patient is a patient in a septic state, more particularly, in septic shock, a patient suffering from burns, more particularly severe burns, a patient suffering from trauma, more particularly severe trauma, or a patient who has undergone surgery, more particularly major surgery.
- said method is characterized in that the biological sample comes from a patient in a septic state, suffering from burns, suffering from trauma or having undergone a surgical operation, and admitted to an intensive care unit .
- said method is characterized in that the complication consists of the occurrence of a healthcare-associated infection (HAI).
- HAI healthcare-associated infection
- said method is characterized in that it comprises the implementation of the steps consisting in: a) measuring the viral load of at least one TTV in a biological sample from said patient, b) comparing the viral load determined for said biological sample with a predetermined reference value, and c) establishing a risk of complication when the viral load determined for said sample is higher or lower than the predetermined reference value.
- said method is characterized in that the predetermined reference value is 10,000 copies/ml.
- said method is characterized in that it comprises the implementation of the steps consisting in: a) measuring a first viral load of at least one TTV in said biological sample of the patient from a first sample taken at time T1, b) measuring a second viral load of at least one TTV in said biological sample of the patient from a second sample taken at time T2, c) calculating the variation between the viral load at T2 and the viral load at T1, giving an ATTV value, d) establishing a conclusion as to the risk of complication, based on the result of the comparisons.
- the method is characterized in that it comprises the implementation of the steps consisting in: a) measuring a first viral load of at least one TTV in said biological sample of the patient from a first sample taken at time T1, b) measuring a second viral load of at least one TTV in said biological sample of the patient from a second sample taken at time T2, c) calculating the variation between the viral load at T2 and the load viral at T1 , giving an ATTV value, d) draw a conclusion as to the absence of an increased risk of complication when the ATTV value is within the range from -1.25 to +1.25, preferably -1.20 to +1.20, and more preferably from -1.10 to +1.10.
- said method is characterized in that it also comprises the detection of the presence of at least one Herpesvirus (HPV).
- HPV Herpesvirus
- said method is characterized in that it also comprises measuring the viral load of at least one Herpesvirus (HPV).
- HPV Herpesvirus
- said at least one Herpesvirus is selected from the group consisting of: CMV, EBV, HHV6 and HSV-1, and is preferably EBV.
- said method is characterized in that the viral load is measured by amplification, sequencing or hybridization of at least one sequence of TTV, and of at least one Herpes virus where appropriate, preferably by amplification , more preferably by real-time PCR.
- said method is characterized in that the biological sample is a biological fluid from the patient, said fluid being selected from the group consisting of: blood or its derivatives such as plasma and/or serum , cerebrospinal fluid, urine, and bronchoalveolar lavages.
- the subject of the present invention is a method for evaluating a risk of complication, for example a healthcare-associated infection (HAI), in a patient not taking immunosuppressive treatment, admitted to a healthcare establishment.
- a risk of complication for example a healthcare-associated infection (HAI)
- HAI healthcare-associated infection
- TTV torque teno virus
- the co-detection from the first week following the patient's admission, particularly in the intensive care unit, of a high viral load in TTV associated with the presence of at least one herpesvirus is correlated with a risk of occurrence of a healthcare-associated infection (HAI).
- HAI healthcare-associated infection
- the subject of the present description is a method for in vitro or ex vivo evaluation of the risk of complications in a patient not taking immunosuppressive treatment, admitted to a health establishment, based on a measurement of the viral load of at least one TTV in a biological sample from said patient.
- a method is described here for the in vitro or ex vivo evaluation of the risk of complication in a patient admitted to a health establishment, comprising measuring the viral load of at least one TTV in a biological sample from said patient, characterized in that said patient is not under immunosuppressive treatment.
- a variation in the viral load in TTV during the first month following admission to the healthcare establishment indicates a risk of developing an HAI.
- the expression "assessment of the risk of complication in a patient” or “determine a risk of complication in a patient” means here the determination of a probability for a given subject or patient to develop a complication, as defined below, in the future.
- the methods disclosed here represent tools for assessing said risk, and can be combined with other methods, methods or indicators such as clinical examination, taking a biological sample from said patient and detecting one or more biomarkers and/or of one or more infectious agents, in particular bacteria, viruses, parasites or yeasts and filamentous fungi.
- plication is meant here the unfavorable evolution of a disease, a state of health or a medical treatment.
- a “complication”, as it is understood here, can be in particular the unfavorable evolution of a disease which may require the installation of one or more invasive medical devices, such as for example a tracheal intubation, the placement of a urinary catheter, the placement of a catheter or a central line.
- plication also means the unfavorable evolution of a disease which may have the effect of extending the duration of care in the said health establishment, in particular in the intensive care unit.
- “Complication” also means the death of said patient.
- the term "complication” also means the unfavorable evolution of a disease that may require the implementation of a specific medical treatment.
- An example of such a complication is the development of a secondary infection or opportunistic infection, in particular a "care-associated infection” or "HAI”, such as an infection by one or more of the infectious agents, for example of bacteria, viruses, parasites or yeasts and filamentous fungi.
- HAI care-associated infection
- an infection is said to be “associated with care”, if it occurs during the management (diagnostic, therapeutic, palliative, preventive, educational or operative) of a patient by a healthcare professional. health, and if she was not present at the start of treatment.
- Healthcare-associated infections include infections contracted in a health facility (known as nosocomial infections) but also during care delivered outside this setting. When the infectious state at the start of treatment is not precisely known, a delay of at least 48 hours or a delay longer than the incubation period is commonly accepted to define an HAI.
- Healthcare-related infection can be of bacterial origin, such as bacteria such as Escherichia coli, Staphylococcus aureus (staphylococcus aureus) or Pseudomonas aeruginosa.
- the infection can also be of fungal origin, in particular by a yeast of the Candida genus, or a filamentous fungus of the Aspergillus genus, in particular Aspergillus fumigatus.
- the infection can also be of the viral type, in particular by a virus of the Adenovirus, Herpesvirus, Enterovirus, Rotavirus or HIV type. It can also be the reactivation of potentially pathogenic latent viruses, such as herpes viruses, for example the CMV, EBV, HHV6 and HSV-1 viruses.
- the description relates to an in vitro or ex vivo method for evaluating a risk of complication in a patient not taking immunosuppressive treatment, said complication being the occurrence of a healthcare-associated infection (HAI).
- HAI healthcare-associated infection
- G IAS can be a nosocomial infection.
- the method described here makes it possible to determine the risk of occurrence of a nosocomial infection in said patient.
- the process described here makes it possible to determine the risk of occurrence of a secondary infection.
- the method described here is based in particular on measuring the viral load of at least one TTV in a biological sample from the patient.
- Bio sample means any sample that can be taken from a subject.
- the biological sample must allow the determination of the TTV and/or Herpesvirus (HPV) load.
- the biological sample includes, but is not limited to, whole blood, serum, plasma, sputum, nasopharyngeal swabs, urine, stool, skin, cerebrospinal fluid, saliva, gastric secretions, semen, seminal fluid, tears, tissue or spinal fluid, cerebral fluid, trigeminal ganglion sample, sacral ganglion sample, adipose tissue, lymphoid tissue, placental tissue, upper reproductive tract tissue, gastrointestinal tract tissue, genital tissue and central nervous system tissue.
- this sample can be a biological fluid, such as a blood sample or a sample derived from blood, which can in particular be chosen from whole blood (as collected from the venous route, that is to say containing the white and red cells, platelets and plasma), plasma, serum, as well as any type(s) of cells extracted from blood, such as peripheral blood mononuclear cells (or PBMC, containing lymphocytes (B, T and NK cells), dendritic cells and monocytes), subpopulations of B cells, purified monocytes, or neutrophils.
- the sample to be tested can be used directly from the biological source or following a pre-treatment to modify the character of the sample.
- pretreatment may include the preparation of plasma from blood, the dilution of viscous fluids, and so on.
- Pretreatment processes may also involve filtration, precipitation, dilution, distillation, mixing, concentration, inactivation of interfering components, addition of reagents, lysis, etc. Additionally, it may be beneficial to modify a solid test sample to form a liquid medium or to release the analyte.
- the biological sample is a biological fluid from the patient, said fluid being selected from the group consisting of: blood or its derivatives such as plasma and/or serum, cerebrospinal fluid, urine, and bronchoalveolar lavages.
- the biological sample is a sample of blood or one of its derivatives such as plasma and/or serum.
- subject herein refers to a vertebrate, preferably a mammal and most preferably a human.
- a human subject may also be called a “patient”.
- patient we refer here more particularly to a human subject who has come into contact with a health professional, such as a doctor (for example, a general practitioner) or a medical structure or a health establishment (for example, a hospital, and more particularly the emergency department, the intensive care unit, an intensive care unit or a continuing care unit, or a medical structure for the elderly, of the EHPAD type).
- a health professional such as a doctor (for example, a general practitioner) or a medical structure or a health establishment (for example, a hospital, and more particularly the emergency department, the intensive care unit, an intensive care unit or a continuing care unit, or a medical structure for the elderly, of the EHPAD type).
- a health professional such as a doctor (for example, a general practitioner) or a medical structure or a health establishment (for example, a hospital, and more particularly the emergency department, the intensive care unit, an intensive care unit or a continuing care unit, or a medical structure for the elderly, of the EHPAD type).
- the patient may be an
- said evaluation method makes it possible to determine the risk of developing a complication in a patient who is not under immunosuppressive treatment.
- “Patient who is not on immunosuppressive treatment” means that said patient is not taking immunosuppressive drugs, or drugs with immunosuppressive side effects, nor is he undergoing any treatment that may induce immunosuppression.
- an “immunosuppressive treatment” may in particular be a treatment implementing glucocorticoids, cytostatics, interferons, antiproliferative and antimetabolic drugs (rapamycin, everolimus, mycophenolate mofetil, mycophenolic acid), inhibitors of calcineurin, in particular for their anti-graft rejection action (ciclosporin, tacrolimus (FK506), voclosporin), S1P-R agonists (FTY720), malononitrilamides (FK778), antibodies such as, for example, antithymocyte globulin or certain monoclonal antibodies directed against specific antigens such as muromonab-CD3, daclizumab, basiliximab, rituximab, ale
- immunosuppressive treatment also means radiotherapy or chemotherapy.
- the description relates to an in vitro or ex vivo method for evaluating a risk of complication in a patient not taking immunosuppressive treatment admitted to a hospital, in particular to the emergency department, intensive care unit, intensive care unit or continuing care unit.
- emergency service is meant the service which concerns the reception of the sick and injured who present themselves spontaneously or brought by ambulances or firefighters' rapid-rescue vehicles.
- the role of the emergency department is to welcome without selection twenty-four hours a day, every day of the year, any person presenting themselves in an emergency situation, including psychiatric, and to take care of them, in particular in case of vital distress and emergency.
- resuscitation service we mean the specialized service where the most serious patients are hospitalized. They benefit from constant monitoring of vital functions such as ventilation, oxygenation, blood pressure, cardiac and renal functions. If necessary, an assistance of these vital functions can be put in place in order to allow the patient's survival if possible. Patients are admitted to intensive care if they have a failure of a vital function such as, for example, during a serious infection (septic shock), drug intoxication, polytrauma, coma, acute renal failure, acute respiratory failure, after cardiac arrest or postoperatively after major surgery such as cardiac or digestive surgery.
- a vital function such as, for example, during a serious infection (septic shock), drug intoxication, polytrauma, coma, acute renal failure, acute respiratory failure, after cardiac arrest or postoperatively after major surgery such as cardiac or digestive surgery.
- intensive care unit or “intensive care service” or “ICU” is meant the service whose mission is to take care of patients in critical condition, that is to say who present a failure of at least least a vital function, or who are at risk of developing a severe complication.
- the intensive care unit has very specialized technical means. These are implemented on an ongoing basis by a multidisciplinary team in order to detect, prevent and correct acute and presumed reversible imbalances related to the underlying condition (illness, surgery, trauma, intoxication, burns, sepsis).
- continuous care unit or “continuous monitoring unit” or “USC”
- continuous monitoring units take care of patients whose condition and treatment raise fears of the occurrence of one or more vital failures patients whose condition, on emerging from one or more vital failures (after a stay in intensive care , for example), is too severe or unstable to allow return to a conventional inpatient unit.
- Continuous monitoring units constitute an intermediate level between resuscitation services on the one hand and conventional care services on the other.
- the present in vitro or ex vivo evaluation method makes it possible to evaluate a risk of complication in a patient admitted to an intensive care unit.
- the present evaluation method is more particularly suited to the evaluation of a risk of complication in a patient who has suffered an immuno-inflammatory attack.
- immuno-inflammatory attack we mean a trauma or injury that has the effect of inducing a hyper-inflammatory response in the patient’s body.
- the persistence of the latter leads to acquired immunosuppression, linked to an anti-inflammatory profile, and ultimately the inability to control infections.
- This phenomenon also known as immunoparalysis, is characterized by the downregulation of the expression of major histocompatibility complex class II molecules on the surface of monocytes, but not B cells. monocyte/macrophage function reduces the release of immune complexes, impairs antigen-presenting abilities, and decreases natural killer cell (NK) cell function.
- NK natural killer cell
- An "immuno-inflammatory attack” includes in particular trauma for patients with trauma, burns for patients with burns, surgery for patients who have undergone surgery or sepsis for patients in a septic state.
- the description relates to an in vitro or ex vivo method for evaluating a risk of complication in a patient not taking immunosuppressive treatment, said patient being in a septic state, more particularly in septic shock, and/or a patient with burn(s), more particularly severe burn(s), and/or a patient with trauma(s), more particularly severe trauma(s), and/or a patient with undergone a surgical operation, more particularly a major surgical operation.
- sepsis patient or “sepsis patient” is meant a patient with at least one life-threatening organ failure caused by an inappropriate host response to an infection.
- septic shock is meant a subtype of sepsis, in which hypotension persists, despite adequate vascular filling.
- “Patient with burn(s)” means that the patient has cellular destruction of the skin and underlying structures caused by a thermal burn and/or an electrical burn and/or a chemical burn and/or a burn by radiation.
- a burn can be superficial, intermediate, or deeper and have a generalized or particular location such as the neck, face, eyes, hands, feet, joints or other parts of the body.
- severe burn(s) or "patient suffering from severe burn(s)” is meant a patient whose burnt body surface is greater than 15% of the total body surface, preferably greater than 20%, preferably greater than 25%, and very particularly greater than 30% of the total surface of the body.
- patient with trauma(s) is meant a patient admitted directly to an intensive care unit.
- Patient with severe trauma(s) means a patient with an injury severity score (ISS, injury severity score, Baker et al, 1974) greater than 15, preferably greater than 20 and more preferably, greater than 25.
- ISS injury severity score
- Surgical patient means a patient who has undergone an invasive surgical procedure intended to treat a medical condition such as disease or injury, to aid or improve bodily function, appearance, or to repair injured areas.
- Major surgery or “patient who has undergone major surgery” means a surgical procedure presenting a technical difficulty and/or presenting a haemorrhagic risk and/or presenting a risk of death and/or long duration (such as example greater than 3 hours, preferably greater than 4 hours such as for example 5 hours or 6 hours, or even more), and/or requiring significant post-operative care.
- major surgery means surgery planned for at least one of the following indications: esophago gastrectomy, Bricker's bladder resection (total resection of the bladder with reconstruction from the small intestine) , cephalic pancreaticoduodenectomy (Whipple procedure) and/or abdominal aortic aneurysm surgery by laparotomy.
- the inventors therefore studied the phenomena of viral reactivation in patients in healthcare establishments. More specifically, they measured the presence and/or the variation of the viral load in TTV in biological samples from said patients at different times during their care in a healthcare establishment.
- the inventors have in particular observed that the viral load could change over time depending on the patient. In particular, they surprisingly found that this change is an indicator of a risk of occurrence of a healthcare-associated infection and/or a risk of extending the duration of treatment. Thus, the inventors have developed a process for in vitro or ex vivo evaluation of the risk of complications in a patient admitted to a healthcare establishment.
- TTV Transmission Teno virus
- a TTV as understood here is a non-enveloped virus, with a circular single-stranded DNA genome of negative polarity.
- TTV genome it is here referred to all the genomes of all the Anelloviridae, and in particular the genomes of the genera Alphatorquevirus (TTV), Betatorquevirus (TTMV), and Gammatorquevirus (TTMDV) found in humans.
- TTV Alphatorquevirus
- TTMV Betatorquevirus
- TTMDV Gammatorquevirus
- TTV-1a the genome of the prototype strain of the Torque Teno virus, TTV-1a. More specifically, an example of a TTV genome is a sequence such as for example that which is represented by SEQ ID No 1 and whose Genbank accession number is AB017610.
- TTV produces chronic infections with no clearly associated clinical manifestation.
- the TTV genome has a size of about 3.8 kb.
- the structure and genomic organization of TTVs is well known to those skilled in the art (cf. for example refer to Biagini, Curr Top Microbiol Immunol.ll'l: 21-33, 2009) and is exemplified in [Fig 1 ].
- the TTV genome can be divided into an untranslated region (UTR) of approximately 1-1.2 kb and a potential coding region of approximately 2.6-2.8 kb.
- the coding region contains in particular two large open reading frames: ORF1 and ORF2, coding two proteins of 770 and 202 residues respectively.
- ORF1 and ORF2 are between nucleotides 589-2901 and 107-715, respectively.
- the TTV genome may have other open reading frames.
- the TTV genome may include two additional reading frames, ORF3 and ORF4 [Fig 1].
- the UTR untranslated region is well conserved. It comprises in particular a GC-rich sequence capable of forming a secondary structure.
- the amplification of selected sequences in the UTR-5' untranslated region has demonstrated that the prevalence of the virus is very high throughout the entire world population (Hu et al., J Clin Microbiol. 43(8) : 3747-3754, 2005).
- This region comprises in particular a sequence of 128 bp and can be amplified by methods known to those skilled in the art, such as for example the TTV R-GENE® diagnostic kit (bioMérieux, France).
- viral load we mean the number of viral particles present in a biological sample. Viral load reflects the severity of a viral infection. The viral load can be determined by measuring the amount of one of the components of the virus (genomic DNA, mRNA, protein, etc.) in the biological sample.
- the viral load thus refers to the proportion of nucleic acid sequences belonging to said virus in a biological sample. More preferentially, the viral load represents the number of copies of the genome of said virus in a biological sample.
- the viral load represents the TTV load.
- the “TTV load” corresponds here more particularly to the TTV viral load, that is to say the number of TTV viral particles present in a biological sample.
- TTV load in a patient means the viral load of any TTV harbored by said patient.
- the TTV load can be determined by measuring the amount of a TTV component in this biological sample.
- the TTV load corresponds to the quantity of TTV nucleic acid sequences present in a biological sample.
- the determination of the TTV load in a patient according to the method of the invention comprises the estimation of the number of sequences of all the TTVs in a biological sample of said patient.
- the detection of a high viral load in TTV and particularly, the detection of a variation in the load in TTV is associated with an increased risk of complication, in particular of occurrence of an infection associated with care, independently of the strain or strains of Anelloviridae detected.
- the determination of the TTV load comprises the determination of the quantity of active and/or inactive viral copies. It consists of determining the quantity of circulating, integrated or latent viral copies.
- limit of detection or “LOD”, is meant the smallest quantity of copy of the genome that can be distinguished from an absence of detection (blank value) using viral standards. Then, by extrapolation from standard curves, it is then possible to determine a viral load in copies of viral DNA per pL in the reaction tube, then in copies of viral DNA per mL in said sample.
- a high TTV viral load is considered to be a viral load in the biological sample greater than 7,000 copies per mL of biological sample such as, for example, blood or one of its derivatives. such as plasma and/or serum, preferably greater than 10,000 copies per mL of plasma, preferably greater than 20,000 copies per mL of sample biological, and more preferably, greater than 40,000 copies per mL of biological sample.
- biological sample such as, for example, blood or one of its derivatives.
- plasma and/or serum preferably greater than 10,000 copies per mL of plasma, preferably greater than 20,000 copies per mL of sample biological, and more preferably, greater than 40,000 copies per mL of biological sample.
- TTV levels - and therefore TTV load - can be determined according to methods well known to those skilled in the art by measuring levels of TTV DNA, TTV RNA or TTV proteins.
- the method according to the invention can thus comprise between the taking of the sample from the patient and step a) as defined below, another preliminary step corresponding to the transformation of the biological sample into a DNA sample. double-stranded, or into a sample of mRNA (or corresponding cDNA), or into a sample of proteins, which is then ready to be used for the in vitro measurement of the viral load in TTV in step a) as as defined below.
- the double-stranded DNA can correspond either to the entire TTV genome, or only to a part of it.
- detection of TTVs can be performed, depending on the type of sample or transformation, either by genomic DNA (i.e. based on the presence of at least one sequence consisting of at least part of the TTV genome), or by mRNA (i.e. based on the TTV mRNA content in the sample), or at the protein level (i.e. based on the TTV protein content in the sample).
- TTV levels are determined by measuring levels of TTV nucleic acid, more preferably TTV DNA.
- Methods for detecting a nucleic acid in a biological sample include, among others, amplification, preferably PCR amplification, more preferably real-time PCR, sequencing, hybridization with a labeled probe.
- the description therefore relates to a method for in vitro or ex vivo evaluation of the risk of complications in a patient not taking immunosuppressive treatment admitted to a health establishment, comprising measuring the viral load of at least one torque teno virus (TTV) in a biological sample from said patient, said viral load being measured by amplification, sequencing or hybridization of at least one TTV sequence preferably by amplification, more preferably by real-time PCR.
- TTV torque teno virus
- the TTV load is determined by amplifying the TTV sequences.
- a preferred approach consists in amplifying sequences which are known to be specific for the TTV genome, and in particular preferably at least one sequence of the UTR untranslated region of the TTVs as defined previously.
- telomere sequence of the TTV genome is meant here a sequence which is present in the majority of the known TTVs, but which is absent from the majority of the other viruses, in particular from the majority of the other anelloviruses.
- a TTV specific sequence is present in at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% of known TTV genomes. More preferably, it is present in 100% of known TTV genomes.
- a TTV-specific sequence is present in less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1% of known non-TTV anellovirus genomes.
- a TTV-specific sequence is absent from all known non-TTV anellovirus genomes.
- a sequence is for example a sequence comprised in the UTR untranslated region which is well conserved from one TTV to another. More particularly, such a sequence can correspond to the 128 bp sequence of the 5'-UTR untranslated region which can be amplified according to methods known to those skilled in the art, for example using the TTV R diagnostic kit - GENE® (bioMérieux, France).
- the method described here comprises the use of primers and probes for the amplification of sequences known to be specific for the TTV genome.
- these primers are preferably oligonucleotides.
- these primers can comprise less than 30 nucleotides, at least 25 nucleotides, less than 20 nucleotides, less than 15 nucleotides or less than 12 nucleotides.
- these primers comprise at least 12, 15, 20.25 or 30 nucleotides.
- the primers used comprise between 12 and 20 nucleotides, between 12 and 25 nucleotides, between 15 and 20 nucleotides or even between 15 and 25 nucleotides.
- the A person skilled in the art knows how to determine the length and the sequence of the primers to be used to amplify the specific sequence(s) of the TTVs. It could, for example, use the same primers as those supplied in the TTV R-GENE® diagnostic kit (ref. 423414 and 69-030B, bioMérieux, France).
- the amplification techniques include in particular isothermal methods and techniques based on PCR (Polymerase Chain Reaction).
- Isothermal amplification methods include a large number of methods. The most used to detect pathogens are the LAMP (Loop-Mediated Amplification) and RPA (Recombinase Polymerase Amplification) methods.
- Isothermal amplification methods also include methods such as, for example, NASBA (nucleic acid sequence-based amplification), HDA (helicase-dependent amplification), RCA (rolling circle amplification) and SDA (strand displacement amplification), EXPAR ( exponential amplification reaction), ICANs (isothermal and chimeric primer-initiated amplification of nucleic acids), SMART (signal-mediated amplification of RNA technology), etc. (see for example Asiallo and Baeumner, Lab Chip 11(8): 1420-1430, 2011).
- NASBA nucleic acid sequence-based amplification
- HDA helicase-dependent amplification
- RCA rolling circle amplification
- SDA strand displacement amplification
- EXPAR exponential amplification reaction
- ICANs isothermal and chimeric primer-initiated amplification of nucleic acids
- SMART signal-mediated amplification of RNA technology
- the PCR technique used quantitatively measures the initial amounts of DNA, cDNA or RNA.
- PCR-based techniques that may be used in the methods described herein include, without limitation, techniques such as real-time PCR (Q-PCR), reverse PCR (RT-PCR), multiplex reverse PCR , real-time reverse PCR (QRT-PCR) and digital PCR (or digital PCR). These techniques are well known technologies and readily available to those skilled in the art.
- the determination of the TTV load is carried out by real-time quantitative PCR.
- Numerous methods for the detection and quantification of TTVs have been described in the art (see for example Maggi et al., J Virol. 77(4): 2418-2425, 2003).
- viral load determination is performed by digital PCR.
- Digital PCR involves multiple PCR runs on extremely dilute nucleic acids such that most positive amplifications reflect the signal from a single template molecule. Digital PCR thus allows the counting of individual model molecules. The proportion of positive amplifications among the total number of PCRs analyzed allows an estimate of the template concentration in the original or undiluted sample. This technique has been proposed to allow the detection of a variety of genetic phenomena (Vogelstein et al., Proc Natl Acad Sci USA 96: 9236-924, 1999). Digital PCR, like real-time PCR, potentially allows the discrimination of fine quantitative differences in target sequences between samples.
- TTV DNA levels are measured by sequencing.
- sequencing is taken in its broadest sense and refers to any technique known to those skilled in the art for determining the sequence of a polynucleotide molecule (DNA or RNA), i.e. that is to say, to determine the succession of nucleotides composing this molecule.
- TTV DNA can thus be sequenced by any technique known in the art. Sequencing as understood herein includes but is not limited to Sanger sequencing, whole genome sequencing, hybridization sequencing, pyrosequencing (including 454 sequencing, Solexa Genome Analyzer sequencing), sequencing with capillary electrophoresis, cycle sequencing, single base extension sequencing, solid phase sequencing, high throughput sequencing, massively parallel signature sequencing (MPSS), reversible dye terminator sequencing, matched pairs, short-term sequencing, sequencing with exonucleases, sequencing by ligation, single molecule sequencing, sequencing by synthesis, sequencing by electron microscopy real-time sequencing, reverse-termination sequencing, sequencing by nanopores, reversible terminator sequencing, semiconductor sequencing, SOLiD(R) sequencing, Single Molecule Real-Tim (SMRT) sequencing e Analysis), MS-PET sequencing, mass spectrometry, and their combinations.
- a particular embodiment uses sequencing high throughput of DNA, using for example the MiSeq, NextSeq 500 platforms, and the HiSeq series developed by Illumina (Reuter et al., Mol Cell, 58: 586-597, 2015; Bentley et al. Nature; 456 : 53-59, 2008), the Genome Sequencer platform from 454 and Roche (Margulies et al.
- High-throughput sequencing also includes methods such as SMRT real-time sequencing (Roads et al., Genomics, Proteomics & Bioinformatics, 13(5): 278-289, 2015), Ion Torrent sequencing (WO 2010/008480; Rothberg et al., Nature, 475: 348-352, 2011) and sequencing using nanopores (Clarke J et al. Nat Nanotechnol: 4: 265-270, 2009).
- Sequencing is performed on all of the DNA contained in the biological sample or on parts of the DNA contained in the biological sample. It is immediately clear to the person skilled in the art that said sample contains at least a mixture of TTV DNA and host subject DNA. Additionally, TTV DNA will likely represent only a minor fraction of the total DNA present in the sample.
- the DNA is randomly fragmented, generally by physical methods, prior to sequencing.
- a first approach consists in sequencing specific sequences of the genome of a TTV species.
- Another approach is to use a method that allows quantitative genotyping of nucleic acids obtained from the biological sample with high precision.
- precision is achieved by analyzing large numbers (e.g., millions or billions) of nucleic acid molecules without any amplification using protocols that rely on knowledge beforehand of the target sequences (that is to say in this case, the sequences of the TTVs).
- the method of the invention comprises a step of quantifying the number of readings.
- a random subset of nucleic acid molecules from the biological sample is subjected to high-throughput sequencing.
- the TTV sequences are identified in the global sequencing data by comparison with publicly deposited TTV sequences. That comparison is advantageously based on the level of sequence identity with a known TTV sequence and makes it possible to detect even remote variants.
- Common software such as BLAST can be used to determine the level of identity between sequences.
- the determination of the TTV load therefore comprises the numbering of the TTV sequences identified by sequencing in the biological sample of the subject.
- the TTV load is determined by measuring the amount of a viral protein in the biological sample. It is thus possible to use specific antibodies, in particular in well-known technologies such as immunoprecipitation, immunohistology, western blot, dot blot, ELISA or ELISPOT, electrochemiluminescence (ECLIA) , protein arrays, antibody arrays, or tissue arrays coupled with immunohistochemistry.
- specific antibodies in particular in well-known technologies such as immunoprecipitation, immunohistology, western blot, dot blot, ELISA or ELISPOT, electrochemiluminescence (ECLIA) , protein arrays, antibody arrays, or tissue arrays coupled with immunohistochemistry.
- FRET or BRET techniques microscopy or histochemistry methods, including in particular confocal microscopy and electron microscopy methods, methods based on the use of one or several excitation wavelengths and a suitable optical method, such as an electrochemical method (the techniques of voltammetry and amperometry), the atomic force microscope, and radiofrequency methods, such as multipolar, confocal resonance spectroscopy and non-confocal, detection of fluorescence, luminescence, chemiluminescence, absorbance, reflectance, transmittance, and birefringence or index of refraction (for example, by surface plasmon resonance, or "surface plasmon resonance" in English, by ellipsometry, by method resonant mirror, etc.), flow cytometry, radioisotopic or magnetic resonance imaging, analysis by polya gel electrophoresis crylamide (SDS-PAGE); by mass spectrometry and by liquid chromatography coupled to mass spectrometry (LC-MS/
- TTV i.e. the amount of TTV DNA, TTV RNA or TTV proteins present in the biological sample to a specific parameter of this sample.
- Normalizing the measured TTV load to a specific parameter reduces the error rate when comparing viral loads from two different biological samples.
- An example of a parameter that can be useful for this normalization can be a physical parameter, independent of the content of the sample, such as its volume, for example. It is also possible to normalize the amount of TTV DNA, TTV RNA or TTV protein to the total amount of DNA, RNA or protein present in the sample. Alternatively, it is possible to use a particular DNA or RNA sequence or a particular protein as a standardization tool. For example, this sequence or this protein can be a human sequence or protein.
- the amount of TTV DNA or RNA or TTV protein in a given sample is compared to an internal control.
- the quantity of nucleic acid or of TTV protein measured in the biological sample can be related to a defined quantity of a nucleic acid or of an appropriate protein which can be identified and quantified, such as an acid nucleic acid or a host or exogenous protein.
- this identifiable and quantifiable nucleic acid or protein is processed (eg, amplified, sequenced, etc.) as the target nucleic acid or protein.
- the preparation steps can include means to protect the viral nucleic acid and destroy the host nucleic acids, for example by using different nucleases.
- these steps may include means to protect viral proteins and destroy host proteins, for example by using different proteases.
- the internal control makes it possible to evaluate the quality and the extent of the processing (for example an amplification or a sequencing) of the molecules considered (nucleic acids or proteins) in the sample.
- said internal control is a nucleic acid molecule of known sequence, this nucleic acid molecule being present in the sample at a known concentration. More preferably, this nucleic acid molecule is the genomic single-stranded circular DNA molecule of a virus of known sequence and concentration in the sample. Such a known virus may for example be a virus from the Circoviridae family.
- the ratio of the number of sequences of the sample to the control makes it possible to estimate the absolute number of TTV genomes of known sequence and concentration.
- this internal control is a protein of known sequence, which is present in the sample at a known concentration.
- TTV load has been determined by measuring the quantity of nucleic acid or TTV protein determined, this being optionally normalized, it may be advantageous to compare it with a predetermined reference TTV load.
- the description relates to an in vitro or ex vivo method for evaluating a risk of complication in a patient not taking immunosuppressive treatment admitted to a healthcare establishment, comprising the implementation of the steps consisting of: a) measuring the viral load of at least one TTV in a biological sample from said patient, b) comparing the viral load determined for said biological sample with a predetermined reference value, and c) establishing a risk of complication when the viral load determined for said sample is higher or lower than the predetermined reference value.
- a reference TTV load or “a reference viral load” is meant within the meaning of the present application any TTV load used as a reference.
- the reference TTV load corresponds to “a reference level of nucleic acid (or protein) of TTV” or “a control level of nucleic acid
- a TTV nucleic acid (or protein) reference concentration is a baseline level measured in a control sample comparable to that tested, and which is obtained from a subject or group of subjects with a particular traumatic and/or infectious state. It may be for example a subject or a group of subjects who are healthy or do not exhibit any particular trauma and/or infection. It may also be a patient or a group of patients admitted to a healthcare establishment, in particular an intensive care unit, in particular a patient or a group of patients who have suffered an immuno-inflammatory attack.
- the reference level can be determined by a plurality of methods.
- the control can be a predetermined value, which can take various forms. It can be a single threshold value, such as a median or mean.
- the “reference level” can be a single value, also applicable to each patient individually.
- the baseline may vary based on specific patient subpopulations. So, for example, older men might have a different baseline than younger men for TTV load, and women might have a different baseline than men for this viral load.
- the "reference level" can be established on the basis of comparative groups, such as groups not having a high level of TTV nucleic acid (or protein) and groups having levels of nucleic acid (or protein) of elevated TTVs.
- comparison groups would be groups with a particular disease, condition, or symptoms and groups without disease.
- the predetermined value may be set, for example, when a test population is divided equally (or unequally) into groups, such as a low-risk group, a medium-risk group, and a high-risk group.
- the reference level can also be determined by comparing the level of nucleic acid (or protein) of TTV in populations of patients suffering from diseases or taking a treatment leading to a state of immunosuppression. This can be accomplished, for example, by histogram analysis, in which an entire cohort of subjects is presented graphically, with a first axis representing the level of said TTV nucleic acid (or protein), and a second axis represents the number of patients in the patient group expressing TTV nucleic acid (or protein) at a given level. Two or more distinct groups of subjects can be determined by identifying subpopulations of the cohort that have the same or similar TTV nucleic acid (or protein) levels.
- a reference level can also represent the levels of two or more of the present TTV nucleic acids (or proteins). Two or more markers can be represented, for example, by a ratio of values for the levels of each marker.
- an apparently healthy population will have a different 'normal' range than a population known to exhibit a condition associated with a high concentration of said TTV nucleic acid (or protein).
- the selected predetermined value may take into account the category into which an individual falls. Appropriate ranges and categories can be selected with just routine experimentation by the skilled person. By raised , augmented , we mean raised relative to a selected control. Generally, control will be based on normal, apparently healthy individuals in an appropriate age range.
- the reference concentration corresponds to the concentration of TTV nucleic acid (or protein) or combination of TTV nucleic acids (or proteins) in the general population.
- the controls in the method described here can be, in addition to predetermined values, biological samples measured in parallel with the samples tested.
- the reference level will be that of the TTV nucleic acid(s) (or proteins) in a sample from a healthy subject.
- the reference concentration of TTV nucleic acid is the concentration of this TTV nucleic acid (or this protein) in a healthy subject or in a population of healthy subjects.
- the reference concentration of the nucleic acid (or protein) of TTV is the concentration of this nucleic acid (or this protein) of TTV in a patient who has suffered an immuno-inflammatory attack or in a group of patients who suffered an immuno-inflammatory attack.
- the reference concentration of the nucleic acid (or protein) of TTV will be the concentration of this nucleic acid (or this protein) of TTV in a patient suffering from sepsis or in a group of patients with sepsis.
- the reference concentration of the TTV nucleic acid (or protein) is the concentration of this TTV nucleic acid (or this protein) in a patient suffering from burn(s) or in a group of patients suffering from burn(s).
- the reference concentration of the nucleic acid (or protein) of TTV is the concentration of this nucleic acid (or this protein) of TTV in a patient suffering from trauma(s) or in a group of patients suffering from trauma.
- the reference concentration of the nucleic acid (or protein) of TTV the concentration of this nucleic acid (or this protein) of TTV in a patient having undergone surgery or in a group of patients having undergone surgery.
- the reference concentration of the nucleic acid (or protein) of TTV the concentration of this nucleic acid (or this protein) of TTV in the same individual having undergone the surgery at a specific time, for example before or just after this one.
- the predetermined reference value corresponds to a viral load in the patient's biological sample, for example blood or one of its derivatives such as plasma and/or serum, greater than 7,000 copies per ml_ of biological sample, for example greater than 10,000 copies, 20,000 copies or even 40,000 copies per ml_ of biological sample.
- a higher TTV viral load in the patient than the predetermined reference value is correlated with the severity of the patient's condition and may also be correlated with an increased risk of complication, in particular the occurrence of healthcare-associated infection.
- the predetermined reference value corresponds to a viral load in TTV of 10,000 copies per ml of biological sample.
- a higher TTV viral load in the patient compared to that of a healthy individual, or group of individuals, may be an indicator that there is an increased risk of compilation in said patient.
- greater means a greater amount, e.g., an amount slightly greater than the original or reference amount, or e.g., an amount in great excess relative to the original or reference quantity, including all quantities in between.
- increase may refer to an amount or activity that is at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% more than the quantity or activity for which the increased quantity or activity is compared.
- lower means a lesser amount, for example, an amount slightly less than the original or reference amount, or for example, a greatly deficient amount. relative to the original or reference quantity, including all quantities in between.
- decrease may refer to an amount or activity that is at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% less than the quantity or activity for which the reduced quantity or activity is being compared.
- the description relates to an in vitro or ex vivo method for evaluating a risk of complication in a patient not taking immunosuppressive treatment, admitted to a health establishment, comprising the implementation of steps consisting of: a) measuring a first viral load of at least one TTV in said biological sample of the patient taken from a first sample taken at time T1, b) measuring a second viral load of at least one TTV in said sample of the patient from a second sample taken at time T2, c) calculate the variation between the viral load at T2 and the viral load at T1, giving an ATTV value, d) establish a conclusion as to the risk of complication, from of the results of the comparisons.
- the inventors have determined that a variation in the viral load in TTV in the patient during his stay in a health establishment, namely an increase or a decrease in the viral load of TTV according to the values defined above -after, is correlated with an increased risk of complications in said patient, in particular an increased risk of developing a healthcare-associated infection.
- the first sample of step a) is taken at a time T1 chosen from: the day of admission, the 1st day, the 2nd day, the 3rd day, the 4th day, the 5th day, the 6th day and the 7th day, it being understood that the first day corresponds to the day after the day of admission and/or the day after the day on which the said patient suffered an immuno-inflammatory attack.
- the first sample of step a) can be taken at the time of the surgery , that is to say just before, just after or during the surgical act.
- the second sampling of step b) is carried out at a time T2, this second time being later than the first time T1 of step a).
- the second sample is taken between the 8th day and the 31st day, and preferably still, between the 14th day and the 31st day.
- the time T2 is preferably chosen from: the 14th day, the 15th day, the 16th day, the 17th day, the 18th day, the 19th day, the 20th day, the 21st day , 22nd day, 23rd day, 24th day, 25th day, 26th day, 27th day, 28th day, 29th day, 30th day and 31st day .
- the second sample is taken after the 31st day, such as at least 40 days, 60 days, 90 days, 100 days, 120 days, 150 days, 180 days, 210 days, 240 days , 270 days, 300 days, 330 days, 360 days after admission of said patient to a health facility.
- the measurement of the viral load in TTV is also carried out on a plurality of samples taken at different times comprised between times T1 and T2.
- the measurement of the viral load in TTV is also carried out on at least 1 sample, preferably at least 2 samples, preferably at least 3 samples, preferably at least 4 samples, preferably at least 5 samples, such as for example 6, 7, or 8 samples taken at different times between times T1 and T2.
- the viral load in TTV at time T1 corresponds to the mean or the median of the viral loads measured in a plurality of biological samples from said patient, taken between the day of admission, and/or immuno-inflammatory attack, and on the 7th day.
- the viral load in TTV at time T1 corresponds to the average or the median of the viral loads measured in at least two, preferably at least three, preferably at least four biological samples from said patient, taken between the day of admission, and/or immuno-inflammatory attack, and on the 7th day.
- the viral load in TTV at time T1 may correspond to the mean or the median of the viral loads measured in biological samples from said patient taken on days 1 or 2, and on days 3 or 4, and on 5, 6 or 7 days.
- the viral load in TTV at time T2 corresponds to the mean or the median of the viral loads measured in a plurality of biological samples from said patient, taken between the 8th day following admission, and/or from immuno-inflammatory attack, and the 31st day.
- the viral load in TTV at time T2 corresponds to the average or the median of the viral loads measured in at least two, preferably at least three, preferably at least four biological samples from said patient, taken between the 8th day following admission, and/or the immuno-inflammatory attack, and the 31st day.
- the viral load in TTV at time T2 may correspond to the average or the median of the viral loads measured in biological samples of said patient taken on the 14th day, or any day between the 13th and on the 18th day, and on the 28th day, or any day between the 26th and 36th day .
- step c) the ATTV value corresponding to the variation between the viral load in TTV at time T2 and the viral load at time T1, i.e.:
- ATTV (viral load in TTV at time T2) - (viral load in TTV at time T1)
- the person skilled in the art is able to calculate the slope of the straight line defined by these two measurements.
- the ATTV thus corresponds to the value of the slope between times T1 and T2.
- the viral load in TTV between times T1 and T2 is stable if the ATTV value is included in the range going from -1.25 to +1.25, preferably in the range going from -1.20 to +1.20, preferably in the range from -1.15 to +1.15, preferably in the range from -1.10 to +1.10.
- viral load stability may correspond to a slope in the range of -1.25 to +1.25 measured between median viral loads for a plurality of samples at T1 and T2.
- the viral load in TTV between times T1 and T2 is increased if the ATTV value is greater than +1.25, preferably greater than +1.35, preferably greater than +1.40 , preferably greater than +1.45, and more preferably greater than +1.50.
- the viral load in TTV between times T1 and T2 is reduced if the ATTV value is less than -1.25, preferably less than -1.35, preferably less than -1.40 , preferably less than -1.45, and more preferably less than -1.50.
- step d) if the viral load change in TTV between time T1 and T2 (ATTV) is in the range from -1.25 to +1.25, it can be concluded in step d) that the patient is not at increased risk of a healthcare-associated infection.
- step d) the patient is at increased risk of developing a healthcare-associated infection.
- the method according to the present description comprises the implementation of the steps consisting in: a) measuring a first viral load of at least one TTV in said biological sample of the patient taken from a first sample taken at time T1, b) measuring a second viral load of at least one TTV in said biological sample of the patient taken from a second sample taken at time T2, c) calculating the variation between the viral load at T2 and the viral load at T1 , giving an ATTV value, d) draw a conclusion as to the absence of an increased risk of complication when the ATTV value is in the range from -1.25 to +1.25, preferably - 1.20 to +1.20, and more preferably from ⁇ 1.10 to +1.10.
- the description relates to an in vitro or ex vivo method for evaluating a risk of complication in a patient not taking immunosuppressive treatment, admitted to a health establishment, comprising measuring the viral load of at least one torque teno virus (TTV) in a biological sample from said patient and further comprising detecting the presence of at least one herpesvirus (HPV) in said biological sample from the patient.
- TTV torque teno virus
- HPV herpesvirus
- the co-detection of a high viral load of TTV and of at least one HPV in the biological sample of the patient, in particular during the first week following his admission to intensive care is an indicator of an increased risk of complications in said patient, in particular an increased risk of developing a healthcare-associated infection.
- the link between early viremia (from the first week after admission) for TTV/Hpv and the existence of an increased risk of developing HAI during the first month is also particularly surprising.
- the term "determination of the presence of at least one herpesvirus" or “detection of at least one herpesvirus” as used herein encompasses qualitative and/or quantitative detection.
- detection of HPV is accomplished by detecting levels of HPV nucleic acid, more preferably HPV DNA.
- a herpesvirus is determined as present or as detected if at least one protein of at least one strain of HPV, more preferably at least one antigen of at least one strain of HPV is detected in at least one biological sample of said patient.
- a herpesvirus is determined as present or detected if at least one nucleic acid of at least one strain of HPV, more preferably at least one DNA of at least one strain of HPV is detected in at least one biological sample of said patient.
- at least one nucleic acid of at least one strain of HPV more preferably at least one DNA of at least one strain of HPV is detected in at least one biological sample of said patient.
- viremia is meant here the level of viral particles, or the viral load, in a biological sample for a given virus.
- the viremia is positive when the number of viral particles detected is greater than a predefined threshold (LOD) in said biological sample for a given virus.
- LOD predefined threshold
- viremia is negative when said viral particles are not detected in said biological sample.
- DNAemia means the detection of viral DNA in a biological sample, in particular in a sample of plasma, whole blood and/or leukocytes isolated from peripheral blood and/or in a sample of buffy coat (the fraction of a sample of unclotted blood after centrifugation that contains most of the white blood cells and platelets).
- Several techniques are available for the detection of DNAemia, including PCR-based techniques, hybrid capture, and branched-chain DNA analysis. When DNA of the virus studied is detected in said biological sample, the DNAemia is positive. On the other hand, the DNAemia is negative when said viral DNA is not detected in said biological sample.
- viral event is meant that a given virus has been detected at least once during the study, and in particular that a positive DNAemia for a given virus has been detected in at least one biological sample from the patient during the duration of the study.
- the patient not taking immunosuppressive treatment presents an increased risk of complication when the TTV viral load in a biological sample of said patient, for example blood or one of its derivatives such as plasma and / or serum, is greater than 7,000 copies per ml_ of biological sample, preferably greater than 10,000 copies per ml_ of biological sample, and that the presence of herpesvirus is also detected.
- the method can thus comprise the implementation of the steps consisting in: a) measuring the viral load of at least one TTV in a biological sample from said patient, b) comparing the viral load determined for said sample biological to a predetermined reference value at 10,000 copies/ml, c) determining the presence of at least one Herpesvirus, preferably by measuring DNAemia, and d) establishing the presence of an increased risk of complication when said load viral determined for said sample is greater than the predetermined reference value and when at least one Herpesvirus is present.
- the description relates to an in vitro or ex vivo method for evaluating a risk of complication in a patient not taking immunosuppressive treatment, admitted to a health establishment, comprising measuring the viral load of at least one torque teno virus (TTV) in a biological sample from said patient and further comprising measuring the viral load of at least one herpesvirus in said biological sample from the patient.
- TTV torque teno virus
- the “viral load of at least one HPV” or “load of at least one HPV” corresponds to the viral load of at least one strain of HPV, that is to say the number of viral particles of at least one strain of HPV present in a biological sample.
- the load of at least one HPV in a patient means the viral load of at least one strain of HPV harbored by said patient.
- the HPV load can be determined by measuring the amount of a component of at least one HPV strain, such as a nucleic acid or a protein, in this biological sample.
- the HPV load corresponds to the quantity of nucleic acid sequences of a given strain of HPV present in a biological sample.
- determining the HPV load includes determining the amount of active and/or inactive viral copies. It consists of determining the quantity of circulating, integrated or latent viral copies.
- the methods for detecting and/or measuring the viral load of an HPV nucleic acid in a biological sample are the same as those previously described for TTV and include, among others, amplification, preferably PCR amplification , more preferably by real-time PCR, sequencing, hybridization with a labeled probe and any other methods known to those skilled in the art.
- Herpesviruses are well known to those skilled in the art. It is a family of DNA viruses affecting various animal species including birds, fish, reptiles, amphibians and mammals, including humans. All members of the HpV family share a common structure: a relatively large, single-partite, double-stranded and linear DNA, encoding 100-200 genes, enclosed in an icosahedral protein cage called the capsid, itself enveloped in a protein coat called integument, containing both viral proteins and viral mRNAs, and a lipid bilayer membrane called the envelope. All HpVs are nuclear replicating, viral DNA is transcribed into mRNA in the nucleus of the infected cell, where it can persist in a latent form indefinitely.
- HpV-1 and HSV-2 herpes simplex viruses 1 and 2
- HSV-1 and HSV-2 herpes simplex viruses 1 and 2
- HHV-1 and HHV-2 herpes simplex viruses 1 and 2
- varicella-zoster virus or HHV-3 which causes chickenpox and shingles
- Epstein-Barr virus (EBV or HHV-4) implicated in several diseases, including mononucleosis and certain cancers and the human cytomegalovirus (HCMV or CMV or HHV-5).
- HHV-6A and HHV-6B human herpesvirus 6A and 6B
- HHV-7 human herpesvirus 7
- KSHV Kaposi's sarcoma-associated herpesvirus
- herpesvirus or “HPV” or “HHV” (Human Herpes Virus) is meant here a virus of the Herpesviridae family.
- HPV genome it is herein referred to the genomes of all Herpesviridae, including those of the HSV-1, HSV-2, HHV-3, EBV, CMV, HHV-6, HHV-7 and KSHV type and more particularly those of the CMV, EBV, HHV6 and HSV-1 type.
- said at least one herpesvirus is selected from the group consisting of: CMV, EBV, HHV6 and HSV-1.
- the herpesvirus is EBV.
- CMV AD169 genome may be the one whose sequence referenced under the Genbank accession number X17403.1.
- EBV B-95 genome may be one whose sequence referenced under the Genbank accession number is V01555.2.
- An example of an HHV6 Z29 genome may be that whose sequence is referenced under the GenBank accession number X83413.2.
- the determination of the presence of at least one HPV and/or the measurement of the HPV viral load is carried out by real-time quantitative PCR.
- Many HPV detection and quantification methods have been described in the art and are known to those skilled in the art (see for example Walton et al., Plos ONE 9(6): e98819, 2014). Reference will be made in particular to the method described by Mallet et al. ( Intensive Care Medicine Exp. (2019) 7:28) and more particularly in table S1 of this article reproduced here in figures 6 and 7. This method is particularly advantageous due to its simplicity and robustness, it can also be implemented implemented with any type of PCR platform.
- the method described herein includes an additional step of normalizing the amount of HPV nucleic acid measured.
- the person skilled in the art may refer to the methods and embodiments described above concerning the normalization of the levels of TTV. These methods can easily be adapted to normalize the amount of HPV nucleic acid.
- the load of at least one HPV has been determined by measuring the quantity of HPV nucleic acid, this being optionally normalized, it may be advantageous to compare it with a reference HPV load.
- the person skilled in the art may refer to the methods and embodiments described above concerning the comparison with reference levels of TTV. These methods can easily be adapted for comparison with reference levels of HPV.
- the patient's susceptibility to the risk of complications, including infections, can therefore be determined using the methods described here, allowing the development of a specific treatment to be tailored to the patient's needs.
- the methods as described above can therefore comprise, in all their embodiments, a healthcare management step, in particular to reduce the risk of complications and in particular the risk of occurrence of an infection associated with healthcare.
- a patient identified as being at increased risk of occurrence of a healthcare-associated infection may have appropriate health care management with the aim of reducing the risk of occurrence of said healthcare-associated infection and, for example, in order to reduce the risk of developing sepsis, septic shock or the risk of death.
- the present description also relates to a method for treating a patient suspected of having a risk of complication, characterized in that it comprises the steps consisting in: identifying the patients presenting a risk of complication by implementing any one of the embodiments as described above and, adapt the health care management of said patient identified in the previous step to reduce the risk of aggravation.
- Examples of care management include an immunomodulatory treatment adapted to the patient or a prophylactic antibiotic treatment, the two treatments can be combined and/or refer to a continuing care or resuscitation service in order to reduce the risk occurrence of a treatment-associated infection, for example reducing the risk of developing sepsis, septic shock or even the risk of death in the days following the measurement of the expression of the biomarker(s).
- the immunomodulatory treatment is an immunostimulatory treatment, if the individual is determined to have an immunosuppressed status, or an anti-inflammatory treatment, if the individual is determined to have an inflammatory status. .
- immunostimulating treatments which can be selected, mention may be made by way of examples of the group of interleukins, in particular IL-7, IL-15 or IL-3, growth factors, in particular GM-CSF, interferons , in particular IFN ⁇ , Toll receptor agonists, antibodies, in particular antibodies directed against immune checkpoints (for example anti-PD1, anti-PDL1, anti-LAG3, anti-TIM3, anti-IL-10 or anti-CTLA4), transferrins and molecules that inhibit apoptosis, FLT3L, Thymosin a1, adrenergic antagonists.
- interleukins in particular IL-7, IL-15 or IL-3
- growth factors in particular GM-CSF
- interferons in particular IFN ⁇
- Toll receptor agonists antibodies, in particular antibodies directed against immune checkpoints (for example anti-PD1, anti-PDL1, anti-LAG3, anti-TIM3, anti-IL-10 or anti-CTLA4)
- glucocorticoids examples include glucocorticoids, cytostatic agents, molecules acting on immunophilins and cytokines, molecules blocking the IL-1 receptor and anti-TNF treatments.
- prophylactic antibiotic treatments to prevent pneumonia are described in particular in the Annales conses d'Anesthésie et de Réanimation (30; 2011; 168-190).
- a patient who does not present a risk of occurrence of a healthcare-associated infection can be quickly referred to a day hospital service, for example an infectiology service, rather than remaining in a service with close monitoring. which he won't need.
- FIG 1 Representation of the genome structure of a TTV isolate.
- FIG 2A Characteristics of patients in the cohort at admission and results according to viral titer in TTV, kinetics of viremia and coinfection with herpesviruses ( Figures 2A and 2B). Categorical variables are expressed in n (%) and continuous variables in median [Q1-Q3]. Comparisons between TTV conditions regarding titer or kinetics of viremia or herpesvirus coinfection were made using a Chi-square test for qualitative variables and a Wilcoxon test for variables quantitative, as appropriate. P values in bold with stars indicate significance at p ⁇ 0.05.
- FIG 4 Characteristics of patients in the cohort at admission and results according to TTV DNAemia greater than 167 copies (cp)/ml (LOD), 7000 copies/ml, 10,000 copies/ml and 40 000 copies/ml, during the first month (D1 to D28) following admission.
- Inclusion criteria were: patients over 18 years of age, clinical diagnosis of sepsis as defined by the 2016 SEPSIS-3 consensus guidelines (Singer et al., 2016), severe trauma with a severity score (ISS) > 15, severe burn with total burn area greater than 30%, or surgical patients undergoing major surgery such as esophagogastrectomy, bladder resection with Brickers reconstruction, cephalic pancreaticoduodenectomy, and abdominal aortic aneurysm surgery by laparotomy.
- the exclusion criteria were as follows: presence of a pre-existing condition or of a treatment that could influence the immune status of the patients, in particular, patients on immunosuppressive treatment, pregnancy, institutionalized patients, inability to obtain informed consent are excluded.
- Patient demographics, comorbidities, diagnosis, severity, and clinical outcomes were manually recorded prospectively. Longitudinal follow-up was carried out for a period of 30 days. Peripheral whole blood collected from each patient and from each healthy volunteer was processed each time within 3 hours of blood collection.
- PAXgene samples were stabilized for at least 2 hours at room temperature after collection and then frozen at -80°C according to the manufacturer's recommendations.
- HCA-associated infection secondary infection at 28 days (D28) and mortality at D28.
- ICU intensive care unit
- the detection limit of TTV was determined using plasma samples comprising a predetermined amount of TTV.
- the control plasma sample is serially diluted from 10 1 to 10 4 , and each diluted sample is independently extracted 3 times and then amplified by quantitative PCR, in order to determine an approximate detection limit.
- the greatest dilution giving a positive signal is diluted again to 1/2, and to 1/4 then each diluted sample is extracted independently 20 times and amplified. The most dilute positive replicates with 100% detection are used as the detection limit.
- the LOD expressed in copies per ml of plasma, is 167 for TTV, 100 for CMV, 33 for EBV, 166 for HHV6, and 33 for HSV1.
- Real-time PCR amplifications of viral DNAs were performed on the StepOnePlusTM Real-Time PCR System (ThermoFisher SCIENTIFIC) using R-GENE® assay kits using TaqMan probes for CMV, EBV , HSV1, HHV6 and TTV (bioMérieux SA). All nucleic acid samples, randomly distributed in the plates, were amplified simultaneously with the quantification standards, sensitivity controls and negative controls, according to the manufacturer's instructions.
- the viremia was evaluated by measuring the DNAemia for each virus, a viremic event, that is to say a positive DNAemia, being characterized by a number of copies of the virus per microliter greater than a predefined threshold (greater than the LOD).
- a positive DNAemia is considered early if it is detected for at least one of the patient's samples during the first week (day 1/2, day 3/4 or day 5/7) after the patient's admission to intensive care. DNAemia was also assessed on D14 and D28. Data are presented as numbers and percentages (qualitative variables) and medians and 25th/75th percentiles (quantitative variables).
- the REALISM cohort of 377 critically ill patients consists of: 107 sepsis, 137 severe trauma, 24 severe burns and 109 major surgeries.
- Quantitative (viral load) rather than qualitative (DNAemia) data may allow better discrimination between (1) insignificant viral load, (2) viral "reactivation" as a putative marker of immunosuppression, and (3) viral loads elevated supporting a true viral infection requiring treatment (Textoris et al., 2017).
- TTV was detected (positive DNAemia) in 217 (58%) of the patients in the cohort, slightly more than in the healthy controls (51%).
- each herpesvirus individually during the first week of admission is not significantly associated with a risk of healthcare-associated infection (HAI), unlike the first month.
- HAI healthcare-associated infection
- a significant increase in the rate of IAS is observed in patients who have had at least one episode during the first month.
- viraemic positive DNA for any of the individual herpesviruses, in the absence of positive DNA for TTV.
- HAIs co-detection, preferably from the first week of admission, of a high viral load in TTV with positive herpes DNAemia is correlated with the risk of more frequent occurrence of HAIs, and (ii) a stable TTV viral load is associated with relatively less occurrence of HAI, in contrast to a variation in the viral load in TTV which is also correlated with the risk of occurrence of IAS in the patient.
- TTV The course of viremia over time was less discernible for TTV (from 58% in the first week to 60% over the month), and positive viremia for TTV was more common for TTV alone than for TTV co-detection -herpesvirus (42% against 15% measured during the first week, 40% against 20% measured during the first month).
- TTV and EBV were the most frequently co-detected viruses, 8% to 10% during the first week and first month, respectively.
- the results demonstrate in patients admitted to the intensive care unit, the existence of a correlation between viral reactivation, in particular TTV in combination or not with HpV, and the risk of development of healthcare-associated infections.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280062978.3A CN117957333A (zh) | 2021-07-19 | 2022-07-19 | 细环病毒(ttv)作为标志物以确定医疗保健机构收治的患者的并发症的风险的用途 |
EP22754486.3A EP4373977A1 (fr) | 2021-07-19 | 2022-07-19 | Utilisation du virus torque teno (ttv) en tant que marqueurs pour determiner le risque de complication chez un patient admis au sein d'un etablissement de sante |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2107771A FR3125300A1 (fr) | 2021-07-19 | 2021-07-19 | Utilisation du virus torque teno (ttv) en tant que marqueurs pour determiner le risque de complication chez un patient admis au sein d’un etablissement de sante |
FRFR2107771 | 2021-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023002120A1 true WO2023002120A1 (fr) | 2023-01-26 |
Family
ID=80122975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2022/051436 WO2023002120A1 (fr) | 2021-07-19 | 2022-07-19 | Utilisation du virus torque teno (ttv) en tant que marqueurs pour determiner le risque de complication chez un patient admis au sein d'un etablissement de sante |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4373977A1 (fr) |
CN (1) | CN117957333A (fr) |
FR (1) | FR3125300A1 (fr) |
WO (1) | WO2023002120A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010008480A2 (fr) | 2008-06-25 | 2010-01-21 | Ion Torrent Systems Incorporated | Procédés et appareil pour mesurer des substances à analyser à l'aide de réseaux fet à grande échelle |
WO2010082004A1 (fr) * | 2009-01-19 | 2010-07-22 | Biomerieux | Procedes pour determiner la susceptibilite a contracter une infection nosocomiale chez un patient et pour etablir un pronostic d'evolution d'un syndrome septique |
FR2941239A1 (fr) * | 2009-01-19 | 2010-07-23 | Biomerieux Sa | Procede pour determiner la susceptibilite a contracter une infection nosocomiale chez un patient presentant une reponse systemique inflammatoire associee ou non a une infection. |
-
2021
- 2021-07-19 FR FR2107771A patent/FR3125300A1/fr active Pending
-
2022
- 2022-07-19 EP EP22754486.3A patent/EP4373977A1/fr active Pending
- 2022-07-19 CN CN202280062978.3A patent/CN117957333A/zh active Pending
- 2022-07-19 WO PCT/FR2022/051436 patent/WO2023002120A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010008480A2 (fr) | 2008-06-25 | 2010-01-21 | Ion Torrent Systems Incorporated | Procédés et appareil pour mesurer des substances à analyser à l'aide de réseaux fet à grande échelle |
WO2010082004A1 (fr) * | 2009-01-19 | 2010-07-22 | Biomerieux | Procedes pour determiner la susceptibilite a contracter une infection nosocomiale chez un patient et pour etablir un pronostic d'evolution d'un syndrome septique |
FR2941239A1 (fr) * | 2009-01-19 | 2010-07-23 | Biomerieux Sa | Procede pour determiner la susceptibilite a contracter une infection nosocomiale chez un patient presentant une reponse systemique inflammatoire associee ou non a une infection. |
Non-Patent Citations (34)
Title |
---|
"Genbank", Database accession no. V01555.2 |
"GenBank", Database accession no. X83413.2 |
ANDREW H WALTON ET AL: "Reactivation of Multiple Viruses in Patients with Sepsis", PLOSONE, vol. 9, no. 6, 1 June 2014 (2014-06-01), pages 1 - 13, XP055540517, DOI: 10.1371/journal.pone.0098819 * |
ANNALES FRANÇAISES D'ANESTHÉSIE ET DE RÉANIMATION, vol. 30, 2011, pages 168 - 190 |
ANUJ KUMAR TYAGI ET AL: "Validation of SYBR Green based quantification assay for the detection of human Torque Teno virus titers from plasma", VIROLOGY JOURNAL, BIOMED CENTRAL, LONDON, GB, vol. 10, no. 1, 11 June 2013 (2013-06-11), pages 191, XP021155607, ISSN: 1743-422X, DOI: 10.1186/1743-422X-10-191 * |
ASIELLOBAEUMNER, LAB CHIP, vol. 11, no. 8, 2011, pages 1420 - 1430 |
BENTLEY ET AL., NATURE, vol. 456, 2008, pages 53 - 59 |
BIAGINI, CURR TOP MICROBIOL IMMURIOL, vol. 331, 2009, pages 21 - 33 |
CLARKE J ET AL., NAT NANOTECHNOL, vol. 4, 2009, pages 265 - 270 |
DAVILA SAM ET AL: "Viral DNAemia and Immune Suppression in Pediatric Sepsis :", vol. 19, no. 1, 1 January 2018 (2018-01-01), US, pages e14 - e22, XP055931690, ISSN: 1529-7535, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756109/pdf/nihms910115.pdf> DOI: 10.1097/PCC.0000000000001376 * |
DE VILLIERS E-MBORKOSKY SSKIMMEL RGUNST KFEI J-W.: "The diversity of torque teno viruses: in vitro replication leads to the formation of additional replication-competent subviral molecules", J VIROL., vol. 85, no. 14, April 2011 (2011-04-01), pages 7284 - 95, XP009153737, DOI: 10.1128/JVI.02472-10 |
FABRIZIO MAGGI ET AL: "TT virus loads and lymphocyte subpopulations in children with acute respiratory diseases.", JOURNAL OF VIROLOGY, vol. 77, no. 16, 1 August 2003 (2003-08-01), pages 9081 - 9083, XP055036247, ISSN: 0022-538X, DOI: 10.1128/JVI.77.16.9081-9083.2003 * |
FOCOSI DANTONELLI GPISTELLO MMAGGI F.: "Torquetenovirus: the human virome from bench to bedside", CLIN MICROBIOL INFECT., vol. 22, no. 7, July 2016 (2016-07-01), pages 589 - 93 |
HINO SMIYATA H.: "Torque teno virus (TTV): current status.", REV MED VIROL., vol. 17, no. 1, 2007, pages 45 - 57 |
HU ET AL., J CLIN MICROBIOL., vol. 43, no. 8, 2005, pages 3747 - 3754 |
KOSULIN KKERNBICHLER SPICHLER HLAWITSCHKA AGEYEREGGER RWITT V ET AL.: "Post-transplant Replication of Torque Teno Virus in Granulocytes", FRONT MICROBIOL., vol. 9, 2018, pages 2956 |
KULIFAJ DORIAN ET AL: "Development of a standardized real time PCR for Torque teno viruses (TTV) viral load detection and quantification: A new tool for immune monitoring", JOURNAL OF CLINICAL VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 105, 11 June 2018 (2018-06-11), pages 118 - 127, XP085426343, ISSN: 1386-6532, DOI: 10.1016/J.JCV.2018.06.010 * |
KULIFAJ ET AL., J CLIN VIROL., vol. 105, 2018, pages 118 - 127 |
MAGGI ET AL., J VIROL., vol. 77, no. 4, 2003, pages 2418 - 2425 |
MAGGI FBENDINELLI M: "Immunobiology of the Torque Teno Viruses and Other Anelloviruses.", 2009, HEIDELBERG: SPRINGER BERLIN HEIDELBERG, pages: 65 - 90 |
MALLET ET AL., INTENSIVE CARE MEDICINE EXP., vol. 7, 2019, pages 28 |
MALLET FRANÇOIS ET AL: "Early herpes and TTV DNAemia in septic shock patients: a pilot study", INTENSIVE CARE MEDICINE EXPERIMENTAL, vol. 7, no. 1, 18 December 2019 (2019-12-18), XP055931989, DOI: 10.1186/s40635-019-0256-z * |
MALLET FRANÇOIS ET AL: "Herpes DNAemia and TTV Viraemia in Intensive Care Unit Critically Ill Patients: A Single-Centre Prospective Longitudinal Study", FRONTIERS IN IMMUNOLOGY, vol. 12, 2 November 2021 (2021-11-02), XP055931987, DOI: 10.3389/fimmu.2021.698808 * |
MARGULIES ET AL., NATURE, vol. 437, 2005, pages 376 - 380 |
MCKERNAN ET AL., GENOME RES, vol. 19, 2009, pages 1527 - 1541 |
NISHIZAWA TOKAMOTO HKONISHI KYOSHIZAWA HMIYAKAWA YMAYUMI M: "A Novel DNA Virus (TTV) Associated with Elevated Transaminase Levels in Posttransfusion Hepatitis of Unknown Etiology", BIOCHEM BIOPHYS RES COMMUN., vol. 241, no. 1, December 1997 (1997-12-01), pages 92 - 7, XP002917290, DOI: 10.1006/bbrc.1997.7765 |
REUTER ET AL., MOL CELL, vol. 58, 2015, pages 586 - 597 |
ROADS ET AL., GENOMICS, PROTEOMICS & BIOINFORMATICS, vol. 13, no. 5, 2015, pages 278 - 289 |
ROTHBERG ET AL., NATURE, vol. 475, 2011, pages 348 - 352 |
SHENDURE ET AL., SCIENCE, vol. 320, 2008, pages 1728 - 1732 |
SPANDOLE SCIMPONERIU DBERCA LMMIHÂESCU G: "Human anelloviruses: an update of molecular, epidemiological and clinical aspects", ARCH VIROL., vol. 160, no. 4, April 2015 (2015-04-01), pages 893 - 908, XP037140026, DOI: 10.1007/s00705-015-2363-9 |
STRASSL ET AL., THE JOURNAL OF INFECTIOUS DESEASES, vol. 218, 2018, pages 1191 - 9 |
VOGELSTEIN ET AL., PROC NATL ACAD SCI USA, vol. 96, 1999, pages 9236 - 924 |
WALTON ET AL., PLOS ONE, vol. 9, no. 6, 2014, pages e98819 |
Also Published As
Publication number | Publication date |
---|---|
FR3125300A1 (fr) | 2023-01-20 |
EP4373977A1 (fr) | 2024-05-29 |
CN117957333A (zh) | 2024-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102649364B1 (ko) | 인간 마이크로바이옴 및 그의 성분의 분석을 위한 무세포 핵산 | |
Furuzawa-Carballeda et al. | Achalasia—an autoimmune inflammatory disease: a cross‐sectional study | |
Wapenaar et al. | The interferon gamma gene in celiac disease: augmented expression correlates with tissue damage but no evidence for genetic susceptibility | |
US20100119474A1 (en) | Chronic obstructive pulmonary disease susceptibility and related compositions and methods | |
JP7464279B2 (ja) | レシピエント血液における移植前トランスクリプトームシグネチャーを使用した急性拒絶反応および腎臓同種異系移植喪失の予測のための方法およびキット | |
EP3384047B1 (fr) | Procede d'evaluation du risque de complications chez les patients qui presentent un syndrome de reponse inflammatoire systemique (sirs) | |
AU2016265726A1 (en) | Detection of T cell exhaustion or lack of T cell costimulation and uses thereof | |
EP3814532A1 (fr) | Procédé pour déterminer in vitro ou ex vivo le statut immunitaire d'un individu | |
FR3085689A1 (fr) | Procede pour determiner in vitro ou ex vivo le statut immunitaire d'un individu | |
WO2023002120A1 (fr) | Utilisation du virus torque teno (ttv) en tant que marqueurs pour determiner le risque de complication chez un patient admis au sein d'un etablissement de sante | |
WO2023141097A1 (fr) | Méthodes de traitement de la colite à éosinophiles | |
FR3075224A1 (fr) | Methode de diagnostic d'une vaginose bacterienne par detection de methanobrevibacter smithii | |
FR3099770A1 (fr) | Methode d’analyse de la perte de diversite bacterienne du microbiome intestinal humain | |
WO2021123387A1 (fr) | Prédiction de manifestations cliniques d'une dysbiose de microbiote intestinal | |
EP4038202A1 (fr) | Procédé pour déterminer la capacité d'un individu à répondre à un stimulus | |
Ambrose et al. | Dysregulation of multiple inflammatory molecules in lymph node and ileum of macaques during RT‐SHIV infection with or without antiretroviral therapy | |
US20240011092A1 (en) | Use of torque teno virus (ttv) as a marker to determine the proliferative capacity of t lymphocytes | |
Canuti et al. | Viral metagenomics in drug-naïve, first-onset schizophrenia patients with prominent negative symptoms | |
FR3139579A1 (fr) | Procédé de détection in vitro ou ex vivo d’un statut immunodéprimé chez un sujet | |
EP3936625A1 (fr) | Diagnostic de rejet de greffe allogénique | |
JP2010522560A (ja) | Hiv疾患制限に関連する遺伝的変異体 | |
WO2024008780A1 (fr) | Determination du risque de deces d'un sujet infecte par un virus respiratoire par mesure du niveau d'expression du gene oas2 | |
WO2024033461A1 (fr) | Methode pour determiner la nature virale ou bacterienne d'une infection | |
EP4303319A1 (fr) | Détermination du risque de décès d'un sujet infecté par un virus respiratoire par mesure du niveau d expression du gène cd74 | |
FR3101423A1 (fr) | Procédé pour déterminer la capacité d’un individu à répondre à un stimulus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22754486 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022754486 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022754486 Country of ref document: EP Effective date: 20240219 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280062978.3 Country of ref document: CN |